CytoSorbents to Present at the Rodman & Renshaw Annual Global Investment Conference

CytoSorbents to Present at the Rodman & Renshaw Annual Global Investment 
Conference 
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 08/28/13 --  CytoSorbents
Corporation (OTCBB: CTSO), a critical care focused company
commercializing its European Union approved CytoSorb(R) blood filter
to treat life-threatening illnesses in the intensive care unit,
President and Chief Executive Officer, Dr. Phillip Chan will present
at the Rodman & Renshaw Annual Global Investment Conference taking
place on September 8-10 in New York City.  
Conference Presentation Details:
 Where: Millennium Broadway Hotel,
145 W 44th Street, New York, NY 10036
 When: Monday, September 9th at
12:30 p.m. 
 Room: 7.03
 Webcast:
http://wsw.com/webcast/rrshq23/CTSO
 Conference Website: www.rodm.com 
About CytoSorbents Corporation 
 CytoSorbents is a critical care
focused therapeutic device company using blood purification to
modulate the immune system -- with the goal of preventing or treating
multiple organ failure in life-threatening illnesses. Organ failure
is the cause of nearly half of all deaths in the intensive care unit,
with little to improve clinical outcome. CytoSorb(R), the Company's
flagship product, is approved in the European Union as a safe and
effective extracorporeal cytokine filter, designed to reduce the
"cytokine storm" that could otherwise cause massive inflammation,
organ failure and death in common critical illnesses such as sepsis,
burn injury, trauma, lung injury, and pancreatitis. These are
conditions where the mortality is extremely high, yet no effective
treatments exist. CytoSorbents' purification technologies are based
on biocompatible, highly porous polymer beads that can actively
remove toxic substances from blood and other bodily fluids by pore
capture and surface adsorption. CytoSorbents has numerous products
under development based upon this unique blood purification
technology, protected by 32 issued US patents and multiple
applications pending, including HemoDefend(TM), ContrastSorb,
DrugSorb, and others. Additional information is available for
download on the Company's website: http://www.cytosorbents.com 
Company Contact:
CytoSorbents Corporation
Dr. Phillip Chan
Chief Executive Officer
(732) 329-8885 ext. *823
pchan@cytosorbents.com 
Investor Contact:
Alliance Advisors, LLC
Alan Sheinwald
(914) 669-0222
asheinwald@allianceadvisors.net 
Valter Pinto
(914) 669-0222 x201
valter@allianceadvisors.net 
Media Contact:
JQA Partners
Jules Abraham
(917) 885-7378
jabraham@jqapartners.com 
 
 
Press spacebar to pause and continue. Press esc to stop.